MedTrace Logo

A Clinical Trail of KJ015 in Patients With HER2-Expressing Solid Tumors

NCT07036185 · Status: NOT_YET_RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 66

Last updated 2025-06-25

No results posted yet for this study

Summary

This is an open-label, multicenter, Phase 1 study to evaluate the safety, tolerability, PK, and preliminary efficacy of KJ015 administered subcutaneously in participants with HER2-expressing solid tumors.

Conditions

Interventions

DRUG

KJ015 Injection (Subcutaneous Injection)

KJ015 is administered via subcutaneous injection, with the dosing frequency set at either Q3W.

Sponsors & Collaborators

  • Shanghai Bao Pharmaceuticals Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-06-24
Primary Completion
2026-12-31
Completion
2027-04-30

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07036185 on ClinicalTrials.gov